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GWASCopy number variation (CNV) is an attractive emerging approach to study the association with various diseases.
We performed a CNV-based genome-wide association study of pulmonary function measures (FEV1, FVC, and
FEV1/FVC) in KARE cohorts. Affymetrix Genome-wide Human SNP Array 5.0 was used tomeasure genome-wide
variation and CNV segmentation was performed using Golden Helix SVS 7.0. Single andmultivariate regressions
were used for the association study using the R statistical package and the Dabatase for Annotation, Visualization
and Integrated (DAVIDv6.7b) tool for the functional annotation.We identiﬁed signiﬁcantly associated1260CNVs
with pulmonary functionmeasures of FEV1 and FVC. Functional gene classiﬁcation and annotation analysis found
5 highly enriched clusters, the BPI/LBP/Plunc superfamily, myosin, serpin peptidase inhibitor, protein tyrosine
phosphatase, and olfactory receptors. According to the functional annotation, gene-based CNVs are likely to be
involved in the pathogenesis and inﬂammatory responsiveness of pulmonary diseases.cho71@snu.ac.kr (S. Cho),
im).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.1. Introduction
Pulmonary function measures identify the physiological state of
lungs and airways and are important indicators for the diagnosis of
pulmonary diseases such as asthma, chronic obstructive pulmonary
disease (COPD), and pulmonary ﬁbrosis [1–3]. The forced expiratory
volume in the ﬁrst second (FEV1), the forced vital capacity (FVC), and
the ratio of FEV1 to FVC aremeasures obtained by spirometry, which is
the commonest test of pulmonary function. FEV1 should be approx-
imately 75–80% of the FVC in healthy adults. In restrictive diseases
such as a pulmonary ﬁbrosis, both FEV1 and FVC are proportionally
decreased and the FEV1/FVC is normal or increased. In obstructive
diseases such as bronchial asthma and COPD, FEV1 is reduced and FVC
is usually normal, which gives a reduced FEV1/FVC value. The
measures provide indexes to assess disease severity and to monitor
the progression of obstructive lung disease over time [2]. Heritability
estimates and twin studies have suggested that genetic factors
contribute to pulmonary function, at least in part, but few genetic
determinants of lung function have been identiﬁed [4–8]. Several
genome-wide association studies (GWAS) identiﬁed signiﬁcant single
nucleotide polymorphisms (SNP) associated with pulmonary function
measures in case–control or cohort populations [9–12]. Geneticassociation studies with different genetic variants in the genes of
interest have been used to verify the association of the genes with
pulmonary function [13–16].
In the past few years, efforts have been made to investigate the
potential effects of copy number variation (CNV) on human health
and disease [17–20]. Both CNV and SNP were used to identify the
association with phenotype variation or susceptibility or resistance to
diseases. CNV encompasses more DNA than SNP and contains entire
genes and their regulatory region [21]. In addition to deletion and
duplication rearrangements, structural variants can alter transcription
of genes by changing the copy number of genes sensitive to a dosage
effect or by disrupting proximal or distant regulatory regions [22,23].
In terms of CNV, genome-wide association studies and the candidate
region approach are growing fast and the statistical algorithms to call
CNV are improving. Few genome-wide studies have identiﬁed the
association of CNV with common complex traits, including autism,
schizophrenia, and obesity in case–control studies [18–20].
In this study, we found CNVs associated with the pulmonary
function (FEV1, FVC, and FEV1/FVC) on a genome-wide scale using
large unrelated healthy adult populations of Korea Associated
Resource (KARE). The cohort data have been applied to GWAS of
SNP for 8 biomedically important quantitative traits and used to
survey CNVs in an East Asian population [24,25]. This study is, to our
knowledge, the ﬁrst CNV-based genome-wide association study with
KARE cohorts and it is focused on the dosage effect of genes included
in the CNVs identiﬁed as signiﬁcant for pulmonary function.
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2.1. Discovery of CNVs associated with pulmonary function measures
From the KARE cohort populations, we extracted a total of 10,534
regions of the CNV by themultivariate segmenting option provided by
Golden Helix SVS 7.0. Single-CNVR regression analysis identiﬁed 1688
CNVs with 3402 intact genes for FVC_%PRED and 720 CNVs with 2122
for FEV1_%PRED at the p value of b0.05 after Bonferroni correction
(Supplementary ﬁgure S1). However, no signiﬁcant CNV was found
for FEV1/FVC_PRED. FEV1 and FVC were highly correlated (correlation
value of 0.81), and we performed multivariate analysis for both
phenotypes and found 1260 signiﬁcant CNVs (Supplementary table
S1). A summary of CNVs associated with the pulmonary function
measures is given in Table 1. The total size of signiﬁcant CNVs was
499 Mb, which occupied about 16% of whole genome. Themedian size
of CNVs was 223 kb (range 7–4985 kb). Based on the criteria of the
intensity ratio ±0.4, the number of CNV loss was 6-fold greater than
those of CNV gain (Table 1). Out of 1260 CNVs, 675 contained genes
intact or in part and 142 CNVs were small enough to be included in a
gene. A total of 2385 intact genes were identiﬁed in CNVs from the
multivariate regression analysis (Supplementary table S2).
2.2. Identiﬁcation of SNP associated with pulmonary function measures
We analyzed the SNPs associated with FEV1 and FVC using PLINK
and identiﬁed 76 SNPs for FVC and 48 for FEV1 (pb0.05). Three genes
(CENPC1, GNPDA2, and ZIC4) were in common with the CNV result.
Out of those SNPs, 19 SNPs for FVC and 10 for FEV1 were reached the
threshold for genome-wide statistical signiﬁcance (pb5×10−08)
(Supplementary table S4). The genomic control values (λgc) were
1.043 and 1.048 for FEV1 and FVC, respectively, and Q–Q plots of the
results were presented in Supplementary ﬁgure S3. Among these SNP
identiﬁed, one SNP (rs10935655) was located in the one of CNV
regions associated with FEV1 and FVC. The CNV region contains two
genes ZIC1 and ZIC4 on chromosome3 and the SNP (rs10935655) was
located about 260 kb upstream of ZIC4. None have reported that ZIC4
(Zic family member 4) are related to FEV1 and FVC so far but few
studies showed that the presence of ZIC4 antibodies was associated
with paraneoplastic cerebellar degeneration (PCD) and small cell lung
cancer (SCLC).
2.3. Replication of genes associated with pulmonary function measures
Genes associated with the pulmonary function measures and/or
pulmonary diseases are in the literature. In this study, we asked
whether any of the genes was replicated. In the multivariate analysis,
we found 14 genes reported in the literature (Table 2). Twelve genes
(IL10, KCNMB1, WISP1, ALOX5AP, TNS1, HTR4, IL4R, TRPV4, CHI3L1,
MSR1, CASP10, and CRHR1) were identiﬁed as SNP variants near and/Table 1
Summary of signiﬁcant CNVs identiﬁed by multivariate regression analysis.
No. of
CNV
Sizes of CNV (bp)
Median Smallest Largest
CNVs associated with FEV1 and FVC 1260 223,267 7098 4,984,527
Log2 ratio≤±0.4 248
Log2 ratioN0.4 (gain) 84 391,642 20,421 3,953,702
Log2 ratiob−0.4(loss) 497 269,953 16,997 4,984,527
Log2 ratio N0.4, b -0.4 (complex) 431 40,482 7,098 4,597,103
CNVs including genes 675 399,225 8,448 4,984,527
CNVs with entire genes 374
CNVs with partial genes 372
CNVs included in a gene 142or within each gene that was associated with the pulmonary function
measures and pulmonary diseases [14,15,26–31]. Microsatellite
polymorphism in HMOX1 has been reported to be associated with
FEV1 and FEV1/FVC, and in/del polymorphism in ACE has been
reported to be associated with asthma beside FEV1 and FEV1/FVC
[32,33].
2.4. Gene ontology and functional annotation
The DAVID v6.7b tool was used for analyzing the functional
annotation of 2384 genes identiﬁed by the multivariate regression
analysis, and 2163 gene ID were mapped to DAVID ID for analyzing
the functional annotation. Gene functional classiﬁcation clustered
genes into 50 groups with highest stringency. Five groups had an
enrichment score of N1.3 with a range of 1.4–1.76 (Fig. 1). The
enrichment groups were BPI/LBP/Plunc superfamily, myosin, serpin
peptidase inhibitor, protein tyrosine phosphatase, and olfactory
receptors. (Genes enriched in each group are listed in Supplementary
table S3.) The gene ontology (GO) of biological process was
represented by the View of GO tree based on genes with common
GO terms (pb0.01). GO terms involving cell surface receptor-linked
signal transduction and Wnt receptor signaling pathway were the
most signiﬁcantly enriched in this analysis. Signiﬁcant GO identiﬁed
by cellular component analysis (pb0.01)wasmostly related tomuscle
components such as myosin and ﬁlament and voltage-gated sodium
channel complex (Table 3). The most signiﬁcant KEGG pathway was
the olfactory transduction containing 67 genes (p=0.002).
3. Discussion
An association study of CNV with complex diseases has become a
more attractive ﬁeld since some CNVs were reported to be associated
with various diseases [17–20]. We identiﬁed 1260 CNVs associated
with pulmonary function measures of FEV1 and FVC. This is
approximately 16% of the genome in KARE cohorts, which appears
to be a little higher than that found in other CNV studies. Yim et al.
[25] studied CNV using other samples of the same KARE populations
and found that CNV covered 8% of the genome. It seems that the
number of CNV regions obtained could vary based on the variation of
boundaries among technical or biological sources and different
algorithms used for analysis. Especially with the association study
between CNVs and diseases, our knowledge of reference human CNV
and statistical analysis is still incomplete. However, we found that
CNV loss count was 6 times higher than CNV gain, which was similar
to an earlier study whose CNV loss count was 4-fold greater than CNV
gain [25].
The validation of our result is to determine whether the genes
identiﬁed by our analysis showed the consistency of those reported
earlier. Most recently, two studies of GWAS for the pulmonary
function using SNP have been published, which identiﬁed multiple
loci associated with the phenotypes [9,34]. We found 2 genes, HTR4
(P.bon=2.15E-03) and TNS1 (P.bon=1.74E-03) in common with
CHARGE consortium studies and the SpiroMeta Consortium [9,34].
However, we do not have any gene in common with the Framingham
Heart Study cohorts [11,12]. It was not surprising that our result had
few genes common with the previous SNP-based GWAS considering
that different SNP-based GWAS often showed different results based
on the statistical methods used for association analysis and the
population structure or history. The result of SNP analysis in KARE
cohorts showed no common genes with other cohorts mentioned
above, even though 3 SNP regions were identiﬁed by the CNV-based
result. In CNV analysis, deciding CNV boundaries and algorithms for
calling CNV regions associated with traits of interest seems to be most
important factors that could affect the results. Unlike SNP, statistical
analyses for GWAS based on CNV are still developing. Since CNV
contains more DNA segment than SNP (≥1kbp), the signiﬁcant SNP
Table 2
List of genes identiﬁed in common between the KARE cohort and earlier association studies.
Gene Chr. P.bon Association in the previous studies Reference
IL10 chr1 6.56E-06 SNP, FEV1, FEV1/FVC Asthma, COPD Lyon et al. [14]
KCNMB1 chr5 5.53E-05 SNP, FEV1, Asthma Seibold et al. [30]
WISP1 chr8 7.88E-04 GWAS, SNP, FEV1, wnt signaling pathway Sharma et al. [31]
ALOX5AP chr13 1.05E-03 SNP, FEV1, asthma Holloway et al. [15]
TNS1 chr2 1.74E-03 GWAS, SNP, COPD, FEV1 Repapi et al. [34], Hancock et al. [9]
HTR4 chr5 2.15E-03 GWAS, SNP, Asthma, FEV1 Repapi et al. [34]], Hancock et al. [9]
TRPV4 chr12 2.54E-03 SNP, FEV1/FVC, COPD Zhu et al. [26]
CHI3L1 chr1 5.45E-03 SNP, FEV1/FVC, asthma Rathcke et al. [29]
MSR1 chr8 1.58E-02 SNP, FEV1, FEV1/FVC, COPD Ohar et al. [28]
CRHR1 chr17 1.72E-02 SNP, FEV1, COPD Kim et al. [27]
HMOX1 chr22 1.89E-02 microsatellite, FEV1, FEV1/FVC Guenegou et al. [33]
ADAM33 chr20 2.44E-02 FEV1, Asthma, Hancock et al. [9]
ACE chr17 3.07E-02 in/del, FEV1, FEV1/FVC asthma Gao et al. [32]
CASP10 chr2 4.89E-02 SNP, FEV1/FVC Smith et al. [16]
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variations were consecutively existed within 1-kb distance around
it. In other words, SNP might be only identiﬁed where their locations
are overlapped within CNV boundaries. In addition to GWAS, we
found another 12 genes (IL10, KCNMB1, ALOX5AP, CHI3LI, TRPV4,
ADAM33, CASP10, WISP1, MSR1, CRHR1, HMOX1, and ACE) that were
reported to be associated with the pulmonary function in association
studies of genetic variants in addition to GWAS. Although there is no
apparent evidence of direct association with the traits of FEV1, FVC, or
FVE1/FVC, we found some other common genes that are strongly or
mildly associated with several pulmonary diseases, such as COPD,
asthma, and idiopathic pulmonary ﬁbrosis (IPF). Boon et al. [35]
constructed gene expression proﬁling between progressive and
relatively stable IPF by serial analysis of gene expression (SAGE)
study. We detected 5 genes (NHLRC2, SRI, NEK4, TAL1, and PLUNC)
highly expressed in the progressive group that were characterized
based on the changes in FVC (≥10%) and DLCO (≥15%) over
12 months. Instead of the genes of interest, we often observed a
tendency to detect other members in the same family of the genes,
which might suggest that other variants of the genes also putatively
contribute to the function for the phenotypes and might provide a
greater chance to identify a novel gene or gene function related to
phenotype.
In general, CNV might not have any genes within it or it can
contain genes intact and/or in part. For the functional analysis of the
CNV-based genes identiﬁed, we selected genes intact in the CNVs to
focus on the dosage effect of CNV on pulmonary function. Gene
Functional Classiﬁcation by the DAVID tool useful for clustering large
gene lists into functionally related groups. The signiﬁcantly enriched
clusters showed that genes identiﬁed from the multivariate regres-
sion analysis appeared to be related to the pathogenesis and theserpin peptidase inhibitor
phosphatase
Olfactory receptor
0
BPI/LBP/Plunc superfamily
myosin
0.5 1 1.5 2
Enrichment score
Fig. 1. Analysis chart of gene functional classiﬁcation based on the DAVID tool.inﬂammatory responsiveness of pulmonary diseases. The most highly
enriched cluster is the BIP/LBP/Plunc superfamily group. Most genes
including PLUNC in this group are located in chromosome 20, which is
known to contribute a novel family, the BIP/LBP/Plunc superfamily,
and appear to mediate host defense function against bacteria in the
oral, nasal, and respiratory epithelia [36,37]. Levels of sPLUNC1
protein are increased in airway ﬂuid from smokers, from people
exposed to irritant chemicals and in sputum from patients with COPD
[38]. The second ranked cluster includes genes in the myosin family.
Myosin is an important component of airway smooth muscle (ASM)
and is involved in smooth muscle contraction and the airway
constriction. ASM in human has several functions of asthma
pathogenesis. In normal lung, ASM assists in regulation of gas
exchange, mucus clearance, defense mechanisms, and coughing, and
in the airways of individuals with asthma, the smooth muscle layer
becomes thicker as the result of increased cell size and/or cell number
[10,39]. MYH11 is the representative gene of the smooth muscle
myosin heavy chain and selective over-expression among its variants
contributes to the airway hyper-responsiveness in asthma [40,41].
Tyrosine phosphorylation is related to the permeability of lung
epithelium. Cigarette smoke is known to increase the permeability of
the lung epithelium, which results in the access of toxins and
pathogens. Mainstream cigarette smoke exposure increased tyrosine
phosphorylation of occludin but not ZO-1 and decreased association
between the two tight junction proteins [42]. Numerous studies have
demonstrated that the imbalance between the serin proteases and
serine protease inhibitors (SERPINs) is involved in the pathogenesis of
COPD [43–45]. There are many members in the SERPIN family and the
most widely recognized genes are SERPINA1 and SERPINA3. SERPINA1
is a candidate gene for COPD, but we were not able to detect it in this
study. Instead, we found SERPINA3 and other members in this family
that have been studied only a little [46,47]. Zhong et al. [47] suggested
that other members of this gene family could be involved in the onset
of COPD and deserve further investigation. The least enrichedTable 3
Gene ontology analysis of cellular component (pb0.01).
GO ID GO term Count p Value
GO:0005859 Muscle myosin complex 12 0.000052
GO:0005863 Striated muscle thick ﬁlament 10 0.000087
GO:0032982 Myosin ﬁlament 10 0.000087
GO:0016460 Myosin II complex 12 0.000117
GO:0030017 Sarcomere 23 0.001027
GO:0043292 Contractile ﬁber 25 0.001244
GO:0044449 Contractile ﬁber part 24 0.001304
GO:0030016 Myoﬁbril 23 0.002966
GO:0001518 Voltage-gated sodium channel complex 6 0.007025
Table 4
Characteristics of cohort participants and pulmonary function measurements.
KARE cohorts Ansan Ansung
Male Female Male Female Male Female
(n=4095) (n=4440) (n=2345) (n=2185) (n=1750) (n=2255)
Age 51.7±8.7 52.5±9.0 48.5±7.4 49.5±8.2 55.9±8.6 55.5±8.8
Smoking status
None smokers (%) 19.2 95.0 21.1 95.7 16.7 94.4
Ex- smokers (%) 31.1 1.4 34.1 1.4 27.0 1.3
Current smokers (%) 49.7 3.6 44.8 2.9 56.2 4.3
Phenotypes
FVC_%PRED 102.0±14.0 107.1±15.0 100.7±12.1 105.6±12.8 103.9±15.9 108.6±16.8
FEV1_%PRED 106.4±16.2 116.6±17.6 106.2±13.9 115.3±15.3 106.5±18.9 117.8±19.4
FEV1/FVC_PRED 74.1±2.0 75.0±1.6 74.7±1.8 75.5±1.5 73.3±2.0 74.5±1.6
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coupled receptor (GPCR) protein. The human OR gene family is a large
multigene family in the genome. These genes basically encode 7
transmembrane-type G-protein-coupled receptors of the cell surface
[48]. The gene products are expressed in the olfactory epithelium in
the nose and function as the ﬁrst odorant receptors. OR gene products
appear to be involved in cell signaling pathway in addition to odorant
receptor pathways. There is no direct functional study of the
relationship between OR and lung function, except that non-
functioning single nucleotide polymorphism in OR4X1 gene was
found to be associated with FEV1/FVC in an individual of the Yamagata
Takahata cohort [49]. The pulmonary function candidate gene, HTR4,
mentioned above, belongs to this group. HTR4 is involved in the
serotonin signaling pathway, which has been implicated in immune-
mediated airway reactivity [9].
We identiﬁed CNVs signiﬁcantly associated with the pulmonary
functionmeasures of FEV1 and FVC in KARE cohorts using genome-wide
association analysis. CNV-based genes analyzed by functional annota-
tion showed that theywere likely tobe involved in thepathogenesis and
inﬂammatory responsiveness of pulmonarydiseases, althoughgenome-
wide CNV association studywith phenotypes or common disease is still
at an early stage and requires more deﬁnitive criteria of CNV boundary
and statistical algorithms for calling CNV for the more robust analysis.
4. Materials and methods
4.1. Cohort description
This studyused thedata of cohorts from theKAREproject [24,25]. For
CNV analysis, we chose 8842 individuals after QC control of genotyping
in the study by Cho et al. [24]. The predicted values for FEV1 (FEV1_%
PRED), FVC (FVC_%PRED), and FEV1/FVC (FEV1/FVC_PRED) from the
cohorts were used for the association study of pulmonary function. Out
of 8842 subjects, 308 were excluded from the analysis because the
phenotypic value or the smoking status was not known. A total of 8535
participants of 39–70 years old were used for the association study and
the characteristics of the cohorts are described in Table 4.
4.2. SNP genotyping, quality control, and association analyses
Genotyping data and quality control were performed by Cho et al.
[24]. Association analysis was done using PLINK. Linear regression
analysis was performed for FEV1 and FVCwith an additive model after
adjustment for sex, age, and areas.
4.3. CNVR segmentation or deﬁning CNVR
The intensity dataof 780,822 SNPandnon-polymorphic probeswere
generated by Affymetrix Genome-wide Human SNP Arrays 5.0 tomeasure the genome-wide variation of CNV. The CEL ﬁle containing the
intensity value was imported into Golden Helix SVS 7.0 for the analysis
of CNV segmentation and discovery (Golden Helix Inc., Bozeman, MT,
USA). In order to normalize the intensity and produce the log2 ratio, we
used the mean intensity value of 8842 samples as a reference to
minimize the technical variability between chips and locations asmuch
as possible. Multivariate algorithm by copy number analysis module
(CNAM) in the Golden Helix SVS 7.0 was used for the segmentation of
chromosomes with a moving window size of 5000, maximum
segments/window 100, minimum number of markers/segment 10,
and a signiﬁcance level of pb0.01 for pairwise permutations (n=1000).4.4. CNV association study of pulmonary function
Boxplot was used to check the distribution of cohort data for the
predicted value for FEV1, FVC, and FEV1/FVC (Supplementary ﬁgure S2).
Single linear regression was used to identify CNVs associated with each
quantitative trait. For the traits that were correlated to each other,
multivariate linear regression analysis was used to detect the regions of
CNVwith the R software. Both regression models were adjusted for sex,
age, area, and smoking statusunder theadditive geneticmodel. Smoking
status was classiﬁed into non-smoker, ex-smoker, or smoker. Multiple
corrections including the Bonferroni correction and FDR were used for
both single and multivariate analysis. Signiﬁcant CNVs were counted at
the normal signiﬁcance level of (pb0.05) after Bonferroni correction.4.5. Functional annotation of CNV-based genes
From the CNVs associated with the phenotypes, we collected the
genes whose entire sequence was located within a CNV. The genes
were annotated using RefGene downloaded from the UCSC genome
browser ver.hg18 (http://genome.ucsc.edu/). We used the list of
genes resulted from the multivariate analysis for functional analysis.
The Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7b was used for analyzing functional classiﬁcation, gene
ontology, and pathway (http://david.abcc.ncifcrf.gov/) [50].
Supplementarymaterials related to this article can be found online
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